The purpose of this study is (1) to establish the feasibility, yield, and clinical impact of a "Test \& Treat TB" strategy on a mobile HIV screening unit in South Africa and (2) to assess the cost and cost-effectiveness of this mobile, integrated HIV/TB screening strategy for maximizing linkage to TB care and treatment completion.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
4,815
iThembalabantu Clinic/AIDS Healthcare Foundation
Durban, KwaZulu-Natal, South Africa
Number of patients who complete tuberculosis treatment
Time frame: 6 months
Proportion of mobile testers screened for tuberculosis
Time frame: 20 months
Proportion of eligible participants able to produce sputum samples
Time frame: 20 months
Prevalence of TB among those tested
Time frame: 20 months
Prevalence of tuberculosis and rifampin resistance
The GeneXpert test can detect rifampin resistant strains of tuberculosis
Time frame: 20 months
Distribution of TB symptoms ascertained from TB symptom screen questionnaire
Time frame: 20 months
Proportion returning to the mobile tester for TB test result
Time frame: 20 months
Linkage to TB care (first visit to a local TB treatment site ascertained from clinic record)
Time frame: 1 month
ART initiation date as documented by clinic record for those HIV co-infected
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.